Loading…
INmune Bio Inc. is projected to rise to $3.02 by 2027, a +56% move from its current price of $1.94. INMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.86 | $1.94 | $2.03 | +0.08% |
| Jul 14 | $1.83 | $1.94 | $2.07 | +0.16% |
| Jul 15 | $1.80 | $1.94 | $2.10 | +0.24% |
| Jul 16 | $1.78 | $1.95 | $2.12 | +0.32% |
| Jul 17 | $1.77 | $1.95 | $2.15 | +0.40% |
| Jul 18 | $1.75 | $1.95 | $2.17 | +0.48% |
| Jul 19 | $1.74 | $1.95 | $2.19 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.74 | $1.95 | $2.19 | +0.56% |
| Week 2 | $1.67 | $1.96 | $2.31 | +1.12% |
| Week 3 | $1.62 | $1.97 | $2.41 | +1.68% |
| Week 4 | $1.58 | $1.98 | $2.50 | +2.25% |
| Week 5 | $1.54 | $1.99 | $2.58 | +2.82% |
| Week 6 | $1.51 | $2.01 | $2.66 | +3.40% |
| Week 7 | $1.49 | $2.02 | $2.73 | +3.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
INmune Bio Inc. is a clinical-stage immunology company focused on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg.
The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc (INMB) currently trades at $1.94 per share, with a market cap of $51.58M, and is ranked 4519. It operates within the Healthcare sector as a clinical-stage immunology company.
The price outlook is grounded in a year-by-year forecast. The 2026 average price is $1.94, with a 30-day range of $1.46 to $2.58, and a max of $2.98. The forecast projects growth beyond 2026, with the 2027 average at $3.02 and the 2030 average at $4.09.
The horizon extends to 2040 with an average of $11.35 and to 2050 with an average of $23.71, while the 2050 maximum is $53.49.
Across the forecast, the implied return on investment grows from 0 in 2026 to 55.9 in 2027, 79.8 in 2028, 106.8 in 2029, 110.6 in 2030, 111.5 in 2031, 136.9 in 2032, 180.2 in 2033, 285 in 2034, 319.1 in 2035, 484.9 in 2040, and 1122.2 in 2050.
A major floor 50.2% below — a decisive break under it would weaken the trend.
The nearest floor, 37.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key INMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.77 | Buy | $1.79 | Buy |
| MA 10 | $1.69 | Buy | $1.70 | Buy |
| MA 20 | $1.52 | Buy | $1.59 | Buy |
| MA 50 | $1.46 | Buy | $1.48 | Buy |
| MA 100 | $1.38 | Buy | $1.50 | Buy |
| MA 200 | $1.56 | Buy | $1.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.50 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 155.43 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 36.62 | Buy |
| Bollinger %B (20,2) | 1.02 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 80.96 | Sell |
| Momentum (10) | 0.45 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 1.84 | Buy |
| ADX (14) | 23.21 | Buy |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70. The price is viewed relative to the 50-day simple moving average near $1.46 and the 200-day simple moving average near $1.56. Support is cited at $1.21 and resistance at $1.94. The 30-day range trades between $1.46 and $2.58, indicating a period of modest volatility with upside potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $1.94 | $2.98 | 0% | Neutral | |
| $2.27 | $3.02 | $4.32 | +56% | Bullish | |
| $2.50 | $3.49 | $5.26 | +80% | Bullish | |
| $2.77 | $4.01 | $6.31 | +107% | Bullish | |
| $2.72 | $4.09 | $6.65 | +111% | Bullish | |
| $2.64 | $4.10 | $6.89 | +111% | Bullish | |
| $2.86 | $4.60 | $7.92 | +137% | Bullish | |
| $3.29 | $5.44 | $9.60 | +180% | Bullish | |
| $4.39 | $7.47 | $13.48 | +285% | Bullish | |
| $4.65 | $8.13 | $14.98 | +319% | Bullish | |
| $5.69 | $11.35 | $22.73 | +485% | Bullish | |
| $10.67 | $23.71 | $53.49 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.12 | $1.94 | $2.49 | +0.00% |
| August 2026 | $1.76 | $2.11 | $2.63 | +9.00% |
| September 2026 | $1.72 | $2.09 | $2.64 | -1.35% |
| October 2026 | $1.79 | $2.19 | $2.81 | +5.06% |
| November 2026 | $1.88 | $2.32 | $3.02 | +5.99% |
| December 2026 | $1.82 | $2.27 | $2.98 | -2.43% |
Click any year to see its month-by-month INMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INMB to range from $1.12 to $2.98 through 2026. The $1.94 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The INMB price prediction for 2027 points to an average of $3.02 (low $2.27, high $4.32) — a potential gain of +56% on today's $1.94. Momentum favours further upside here.
In 2028, INMB is projected to trade between $2.50 and $5.26, averaging $3.49 — a potential gain of +80% from today's $1.94. That is up +15% on the projected 2027 average. Buyers look set to stay in control over this stretch.
INmune Bio Inc.'s 2029 outlook centres on $4.01, within a $2.77 to $6.31 range. That is up +15% on the projected 2028 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2030, INMB could reach as high as $6.65, with a base case around $4.09 and support toward $2.72 — roughly +111% from $1.94. Buyers look set to stay in control over this stretch.
Expect INMB to range from $2.64 to $6.89 through 2031. The $4.10 average target implies a +111% move from current prices. That is up 0% on the projected 2030 average. Momentum favours further upside here.
The INMB price prediction for 2032 points to an average of $4.60 (low $2.86, high $7.92) — a potential gain of +137% on today's $1.94. Buyers look set to stay in control over this stretch.
In 2033, INMB is projected to trade between $3.29 and $9.60, averaging $5.44 — a potential gain of +180% from today's $1.94. That is up +18% on the projected 2032 average. Momentum favours further upside here.
INmune Bio Inc.'s 2034 outlook centres on $7.47, within a $4.39 to $13.48 range. That is up +37% on the projected 2033 average. That marks a +285% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, INMB could reach as high as $14.98, with a base case around $8.13 and support toward $4.65 — roughly +319% from $1.94. Momentum favours further upside here.
Expect INMB to range from $5.69 to $22.73 through 2040. The $11.35 average target implies a +485% move from current prices. That is up +40% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The INMB price prediction for 2050 points to an average of $23.71 (low $10.67, high $53.49) — a potential gain of +11.2x on today's $1.94. Momentum favours further upside here.
Investing $1,000 in INMB today (≈ 515.463918 INMB) could be worth
$12,221.61
+$11,221.61 (+1122%) by 2050 · US Dollar
Based on the average projected INMB price of $23.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INMBwould be worth at today's price.
$1,000 invested in INMB on Jul 10, 2025 (≈ 448.430489 INMB) would be worth
$869.96
-$130.04 (-13.0%) today · 0.87× · US Dollar
Based on a INMB entry price of $2.23 vs. today's $1.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.7 | $1,141.18 | +14.1% |
| 1 month ago | $1.21 | $1,603.31 | +60.3% |
| 3 months ago | $1.18 | $1,644.07 | +64.4% |
| 6 months ago | $1.47 | $1,319.73 | +32.0% |
| 1 year ago | $2.23 | $869.96 | -13.0% |
| All time (5.0y) ago | $26.68 | $72.71 | -92.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INMB forecast.
Our base-case forecast reaches $3.90 around 2029.
Implied market cap at $3.90: $103.68M
The multi-year forecast shows a bullish trajectory with meaningful upside over time. In 2030 the average price is forecast at $4.09, with a ROI of 110.6. By 2040 the average price is forecast at $11.35, with a ROI of 484.9. In 2050 the average price is forecast at $23.71, with a ROI of 1122.2.
The forecast also notes earlier years such as 2033, 2034 and 2035, with 2033 average $5.44 (ROI 180.2%), 2034 average $7.47 (ROI 285%), and 2035 average $8.13 (ROI 319.1%). These are estimates and not guarantees, and actual results depend on numerous factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.09, with a minimum of $2.72 and a maximum of $6.65, and a projected ROI of 110.6; sentiment is BULLISH.
Forecasts show a generally bullish trajectory after 2026, with rising averages (2027 $3.02, 2028 $3.49, 2029 $4.01, 2030 $4.09) and higher long-term upside (2040 $11.35, 2050 $23.71; ROI up to 1122.2). These are estimates, not guarantees, and involve risk.
The 2050 maximum forecast is $53.49, which would exceed $50, indicating the target is within the forecast range. The 2050 max is $53.49; these are not guarantees.
Current price is $1.94 and market cap is $51.58M.
Sentiment is BULLISH with RSI(14) at 70. The 50-day SMA is $1.46 and the 200-day SMA is $1.56, with support at $1.21 and resistance at $1.94. The 30-day range is $1.46 to $2.58.
INmune Bio Inc. Community Discussion
0Share your INmune Bio Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.